COVID-19 VACCINE ELIGIBILITY GUIDE

This guide contains information to help individuals determine their eligibility for the COVID-19 vaccine and vaccine booster shots. This guide is updated regularly as vaccine eligibility guidelines change. Use the tabs below to determine your eligibility for the COVID-19 vaccine.

PRIMARY VACCINATION SERIES:

Eligible to receive a COVID-19 Vaccine manufactured by Pfizer-BioNTech or Moderna.

Eligible to receive a third dose of the Moderna vaccine only if you have a compromised immune system.

The third vaccine dose should be administered at least one month following completion of the two-dose primary vaccination series with the Moderna vaccine.

Eligible to receive a COVID-19 vaccine manufactured by Pfizer-BioNTech or Moderna.

Eligible to receive a third dose of the Pfizer-BioNTech or Moderna vaccine only if you have a compromised immune system.

The third Pfizer-BioNTech vaccine dose should be administered at least 28 days following completion of the two-dose primary vaccination series with the Pfizer-BioNTech vaccine.

The third Moderna vaccine dose should be administered at least one month following completion of the two-dose primary vaccination series with the Moderna Vaccine.

Eligible to receive a COVID-19 vaccine manufactured by Pfizer-BioNTech or Moderna.

Eligible to receive a third dose of the Pfizer-BioNTech or Moderna vaccine only if you have a compromised immune system.

The third vaccine dose should be administered at least 28 days following completion of the two-dose primary vaccination series with the Pfizer-BioNTech vaccine.

The third Moderna vaccine dose should be administered at least one month following completion of the two-dose primary vaccination series with the Moderna Vaccine.

Eligible to receive a COVID-19 vaccine manufactured by Pfizer-BioNTech or Moderna.

Eligible to receive a third dose of the Pfizer-BioNTech or Moderna vaccine only if you have a compromised immune system.

The third vaccine dose should be administered at least 28 days following completion of the two-dose primary vaccination series with the Pfizer-BioNTech vaccine.

The third Moderna vaccine dose should be administered at least one month following completion of the two-dose primary vaccination series with the Moderna Vaccine.

Eligible to receive a COVID-19 vaccine manufactured by Johnson & Johnson, Moderna, or Pfizer-BioNTech.

Eligible to receive a third dose of the Moderna or Pfizer-BioNTech vaccine only if you have a compromised immune system. 

The third vaccine dose should be administered at least 28 days following completion of the two-dose primary vaccination series with the same vaccine.

Eligible to receive a COVID-19 vaccine manufactured by Johnson & Johnson, Moderna, or Pfizer-BioNTech.

Eligible to receive a third dose of the Moderna or Pfizer-BioNTech vaccine only if you have a compromised immune system. 

The third vaccine dose should be administered at least 28 days following completion of the two-dose primary vaccination series with the same vaccine.

FIRST BOOSTER DOSE:

Eligible to receive a COVID-19 vaccine booster manufactured by Pfizer-BioNTech at least five months after completion of the primary vaccination series.

Eligible to receive a COVID-19 vaccine booster manufactured by Pfizer-BioNTech at least five months after completion of the primary vaccination series.

Eligible to receive a COVID-19 vaccine booster manufactured by Johnson & Johnson, Moderna, or Pfizer-BioNTech.

Recipients of an mRNA COVID-19 vaccine may receive a vaccine booster, regardless of the manufacturer, at least five months after completion of the primary vaccination series.

Recipients of the Johnson & Johnson COVID-19 vaccine may receive a vaccine booster, regardless of the manufacturer, at least two months after completing the primary vaccination.

SECOND BOOSTER DOSE:

Eligible to receive a second COVID-19 vaccine booster manufactured by Pfizer-BioNTech at least four months after receiving the first booster dose only if you have a compromised immune system.

Eligible to receive a second COVID-19 vaccine booster manufactured by Pfizer-BioNTech or Moderna at least four months after receiving the first booster dose only if you have a compromised immune system.

Eligible to receive a second COVID-19 vaccine booster manufactured by Moderna or Pfizer-BioNTech at least four months after receiving the first booster dose.

NOTES AND SOURCES:

  • The availability of these vaccines and vaccine boosters may be subject to Emergency Use Authorization, which is a status granted by the U.S. Food and Drug Administration (FDA) that authorizes unapproved medical products or unapproved uses of approved medical products to be used during emergencies. These medical products are temporarily authorized to diagnose, treat, or prevent life-threatening diseases when there are no available alternatives.

  • On May 5, 2022, the U.S. FDA limited the use of the Johnson & Johnson/Janssen COVID-19 Vaccine to (1) individuals 18 years of age and older who are unable to obtain an alternative COVID-19 Vaccine due to a lack of accessibility or clinical appropriateness and (2) individuals 18 years of age and older who elect to receive the Johnson & Johnson/Janssen COVID-19 Vaccine because they would not otherwise receive a COVID-19 Vaccine.
  • Immunocompromised individuals may receive both an additional full dose of an mRNA COVID-19 vaccine as well as a booster dose of an mRNA COVID-19 vaccine.

  • A list of underlying health conditions that place an individual at high-risk for severe COVID-19 can be found here.
  • Pandemic Patients recommends consulting with your health care provider to discuss getting vaccinated against COVID-19.

  • This page was last updated on 6/17/2022.

Sources:

“Coronavirus (COVID-19) Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals,” U.S. Food and Drug Administration, August 12, 2021, https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-certain-immunocompromised.

“FDA Approves First COVID-19 Vaccine,” U.S. Food and Drug Administration, August 23, 2021, https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine.

“People with Certain Medical Conditions,” U.S. Centers for Disease Control and Prevention, Updated on October 14, 2021, https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html.

“Coronavirus (COVID-19) Update: FDA Takes Additional Actions on the Use of a Booster Dose for COVID-19 Vaccines,” U.S. Food and Drug Administration, October 20, 2021, https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-additional-actions-use-booster-dose-covid-19-vaccines.

“Moderna COVID-19 Vaccine,” U.S. Food and Drug Administration, Updated on October 20, 2021, https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine.

“Janssen COVID-19 Vaccine,” U.S. Food and Drug Administration, Updated on October 22, 2021, https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/janssen-covid-19-vaccine.

“Comirnaty and Pfizer-BioNTech COVID-19 Vaccine,” U.S. Food and Drug Administration, Updated on October 26, 2021, https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine.

“Spikevax and Moderna COVID-19 Vaccine,” U.S. Food and Drug Administration, Updated on 2/23/2022, https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/spikevax-and-moderna-covid-19-vaccine.

“FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Children 5 through 11 Years of Age,” U.S. Food and Drug Administration, October 29, 2021, https://www.fda.gov/news-events/press-announcements/fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use-children-5-through-11-years-age.

“Emergency Use Authorization,” U.S. Food and Drug Administration, Updated on October 29, 2021, https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization.

“Coronavirus (COVID-19) Update: FDA Expands Eligibility for COVID-19 Vaccine Boosters,” U.S. Food and Drug Administration, November 19, 2021, https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-expands-eligibility-covid-19-vaccine-boosters.

“Coronavirus (COVID-19) Update: FDA Expands Eligibility for Pfizer-BioNTech COVID-19 Booster Dose to 16- and 17-Year-Olds,” U.S. Food and Drug Administration, December 9, 2021, https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-expands-eligibility-pfizer-biontech-covid-19-booster-dose-16-and-17.

“Coronavirus (COVID-19) Update: FDA Takes Multiple Actions to Expand Use of Pfizer-BioNTech COVID-19 Vaccine,” U.S. Food and Drug Administration, January 3, 2022, https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-multiple-actions-expand-use-pfizer-biontech-covid-19-vaccine.

“Coronavirus (COVID-19) Update: FDA Shortens Interval for Booster Dose of Moderna COVID-19 Vaccine to Five Months,” U.S. Food and Drug Administration, January 7, 2022, https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-shortens-interval-booster-dose-moderna-covid-19-vaccine-five-months.

“Coronavirus (COVID-19) Update: FDA Takes Key Action by Approving Second COVID-19 Vaccine,” U.S. Food and Drug Administration, January 31, 2022, https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-key-action-approving-second-covid-19-vaccine.

“Coronavirus (COVID-19) Update: FDA Authorizes Second Booster Dose of Two COVID-19 Vaccines for Older and Immunocompromised Individuals,” U.S. Food and Drug Administration, March 29, 2022, https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-second-booster-dose-two-covid-19-vaccines-older-and.

“Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals,” U.S. Food and Drug Administration, May 5, 2022, https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-janssen-covid-19-vaccine-certain-individuals.

“Coronavirus (COVID-19) Update: FDA Authorizes Moderna and Pfizer-BioNTech COVID-19 Vaccines for Children Down to 6 Months of Age,” U.S. Food and Drug Administration, June 17, 2022, https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-and-pfizer-biontech-covid-19-vaccines-children.

Did you find this information helpful? Please consider making a donation to support our work.

Pandemic Patients is a 501(c)(3) non-profit organization that works to relieve the harm caused by COVID-19 and post-COVID conditions. EIN 86-3930257.

Please consider making a charitable donation to help us advance our important work.

Prior to using this website, please review our Terms of Use and Privacy Policy.